NCT02500199: Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Has active central nervous system (CNS) metastases; CNS metastases allowed if clinically stable for at least 4 weeks- see trial for details
https://ClinicalTrials.gov/show/NCT02500199

Comments are closed.

Up ↑